Jaguar Animal Health (NASDAQ:JAGX) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen cut shares of Jaguar Animal Health (NASDAQ:JAGX) to a strong sell rating in a research report report published on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2,100.00.

Jaguar Animal Health Trading Down 3.9%

Shares of JAGX opened at $6.69 on Friday. The firm’s 50 day simple moving average is $16.45 and its 200 day simple moving average is $33.87. The company has a market capitalization of $2.48 million, a P/E ratio of -0.20 and a beta of 0.02. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.50 and a quick ratio of 0.29. Jaguar Animal Health has a 1-year low of $6.63 and a 1-year high of $462.00.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.